GSK PLC Sponsored ADR $GSK Shares Bought by First Bank & Trust

First Bank & Trust grew its stake in GSK PLC Sponsored ADR (NYSE:GSK) by 61.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 51,151 shares of the pharmaceutical company’s stock after purchasing an additional 19,484 shares during the quarter. First Bank & Trust’s holdings in GSK were worth $2,208,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. NewEdge Advisors LLC grew its position in shares of GSK by 8.6% during the first quarter. NewEdge Advisors LLC now owns 90,663 shares of the pharmaceutical company’s stock worth $3,512,000 after acquiring an additional 7,148 shares during the last quarter. Miller Howard Investments Inc. NY grew its holdings in GSK by 0.8% in the 2nd quarter. Miller Howard Investments Inc. NY now owns 1,659,814 shares of the pharmaceutical company’s stock worth $63,737,000 after buying an additional 13,023 shares in the last quarter. Acadian Asset Management LLC increased its position in GSK by 201.9% in the 1st quarter. Acadian Asset Management LLC now owns 3,982,324 shares of the pharmaceutical company’s stock valued at $154,244,000 after acquiring an additional 2,663,270 shares during the period. TD Private Client Wealth LLC raised its stake in shares of GSK by 997.5% during the second quarter. TD Private Client Wealth LLC now owns 78,019 shares of the pharmaceutical company’s stock valued at $2,996,000 after purchasing an additional 70,910 shares in the last quarter. Finally, Bard Financial Services Inc. increased its stake in shares of GSK by 10.2% during the second quarter. Bard Financial Services Inc. now owns 134,745 shares of the pharmaceutical company’s stock valued at $5,174,000 after acquiring an additional 12,500 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Ratings Changes

GSK has been the topic of several research reports. HSBC reiterated a “reduce” rating on shares of GSK in a research report on Wednesday, December 10th. Jefferies Financial Group reiterated a “buy” rating on shares of GSK in a research report on Monday, October 27th. Weiss Ratings restated a “buy (b)” rating on shares of GSK in a research report on Monday, December 15th. Bank of America raised shares of GSK from an “underperform” rating to a “neutral” rating in a research note on Tuesday, November 25th. Finally, Wall Street Zen upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, GSK currently has an average rating of “Hold” and a consensus price target of $44.13.

GSK Price Performance

Shares of GSK stock opened at $48.58 on Friday. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $49.44. The firm has a market cap of $99.07 billion, a P/E ratio of 13.72, a price-to-earnings-growth ratio of 1.32 and a beta of 0.45. The firm’s 50-day simple moving average is $46.81 and its 200-day simple moving average is $42.13. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.55 and a current ratio of 0.84.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.22. GSK had a return on equity of 48.64% and a net margin of 17.16%.The firm had revenue of $11.35 billion during the quarter, compared to analyst estimates of $8.21 billion. During the same period in the prior year, the company posted $0.50 earnings per share. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. As a group, research analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 8th. Shareholders of record on Friday, November 14th will be paid a $0.4171 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $1.67 dividend on an annualized basis and a yield of 3.4%. GSK’s payout ratio is currently 46.33%.

Insider Buying and Selling

In related news, major shareholder Plc Gsk acquired 1,470,000 shares of the stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $19.00 per share, for a total transaction of $27,930,000.00. Following the transaction, the insider owned 18,245,691 shares of the company’s stock, valued at $346,668,129. The trade was a 8.76% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 10.00% of the stock is currently owned by corporate insiders.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.